Thrombosis in multiple myeloma (MM)

Gabriela Cesarman-Maus, Esteban D Braggio, Rafael Fonseca

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

Thrombosis is a frequent feature in individuals with myeloma, particularly those treated with oral immunomodulatory drugs (IMID) such as thalidomide or lenalidomide concomitantly with anthracyclines or dexamethasone. Up to a third of these individuals may develop venous thrombosis if not given the benefit of prophylaxis. Interestingly, in contrast to individuals with solid tumors in whom thrombosis is a marker of poor prognosis, thrombosis does not impact overall survival in patients with myeloma. This finding suggests that the mechanisms of thrombosis in hematological neoplasms may differ from solid epithelial tumors and that thrombosis in the former may be driven by therapy and not by a procoagulant phenotype of the neoplastic plasma cells. This may also explain why thrombosis in the context of IMID-based therapy may be prevented by the use of prophylactic aspirin. In this text, we review the pathogenesis of thrombosis in myeloma, its relation to different chemotherapeutic regimens and the use of thrombo-prophylaxis.

Original languageEnglish (US)
JournalHematology
Volume17
Issue numberSUPPL. 1
DOIs
StatePublished - Apr 2012

Fingerprint

Multiple Myeloma
Thrombosis
cancer procoagulant
Thalidomide
Anthracyclines
Hematologic Neoplasms
Plasma Cells
Venous Thrombosis
Dexamethasone
Aspirin
Neoplasms
Phenotype
Survival
Therapeutics
Pharmaceutical Preparations

Keywords

  • Multiple myeloma
  • Thrombosis

ASJC Scopus subject areas

  • Hematology

Cite this

Thrombosis in multiple myeloma (MM). / Cesarman-Maus, Gabriela; Braggio, Esteban D; Fonseca, Rafael.

In: Hematology, Vol. 17, No. SUPPL. 1, 04.2012.

Research output: Contribution to journalArticle

Cesarman-Maus, Gabriela ; Braggio, Esteban D ; Fonseca, Rafael. / Thrombosis in multiple myeloma (MM). In: Hematology. 2012 ; Vol. 17, No. SUPPL. 1.
@article{8f2734c00dd54e5fb4416bb22d12cfe6,
title = "Thrombosis in multiple myeloma (MM)",
abstract = "Thrombosis is a frequent feature in individuals with myeloma, particularly those treated with oral immunomodulatory drugs (IMID) such as thalidomide or lenalidomide concomitantly with anthracyclines or dexamethasone. Up to a third of these individuals may develop venous thrombosis if not given the benefit of prophylaxis. Interestingly, in contrast to individuals with solid tumors in whom thrombosis is a marker of poor prognosis, thrombosis does not impact overall survival in patients with myeloma. This finding suggests that the mechanisms of thrombosis in hematological neoplasms may differ from solid epithelial tumors and that thrombosis in the former may be driven by therapy and not by a procoagulant phenotype of the neoplastic plasma cells. This may also explain why thrombosis in the context of IMID-based therapy may be prevented by the use of prophylactic aspirin. In this text, we review the pathogenesis of thrombosis in myeloma, its relation to different chemotherapeutic regimens and the use of thrombo-prophylaxis.",
keywords = "Multiple myeloma, Thrombosis",
author = "Gabriela Cesarman-Maus and Braggio, {Esteban D} and Rafael Fonseca",
year = "2012",
month = "4",
doi = "10.1179/102453312X13336169156933",
language = "English (US)",
volume = "17",
journal = "Hematology",
issn = "1024-5340",
publisher = "Taylor and Francis Ltd.",
number = "SUPPL. 1",

}

TY - JOUR

T1 - Thrombosis in multiple myeloma (MM)

AU - Cesarman-Maus, Gabriela

AU - Braggio, Esteban D

AU - Fonseca, Rafael

PY - 2012/4

Y1 - 2012/4

N2 - Thrombosis is a frequent feature in individuals with myeloma, particularly those treated with oral immunomodulatory drugs (IMID) such as thalidomide or lenalidomide concomitantly with anthracyclines or dexamethasone. Up to a third of these individuals may develop venous thrombosis if not given the benefit of prophylaxis. Interestingly, in contrast to individuals with solid tumors in whom thrombosis is a marker of poor prognosis, thrombosis does not impact overall survival in patients with myeloma. This finding suggests that the mechanisms of thrombosis in hematological neoplasms may differ from solid epithelial tumors and that thrombosis in the former may be driven by therapy and not by a procoagulant phenotype of the neoplastic plasma cells. This may also explain why thrombosis in the context of IMID-based therapy may be prevented by the use of prophylactic aspirin. In this text, we review the pathogenesis of thrombosis in myeloma, its relation to different chemotherapeutic regimens and the use of thrombo-prophylaxis.

AB - Thrombosis is a frequent feature in individuals with myeloma, particularly those treated with oral immunomodulatory drugs (IMID) such as thalidomide or lenalidomide concomitantly with anthracyclines or dexamethasone. Up to a third of these individuals may develop venous thrombosis if not given the benefit of prophylaxis. Interestingly, in contrast to individuals with solid tumors in whom thrombosis is a marker of poor prognosis, thrombosis does not impact overall survival in patients with myeloma. This finding suggests that the mechanisms of thrombosis in hematological neoplasms may differ from solid epithelial tumors and that thrombosis in the former may be driven by therapy and not by a procoagulant phenotype of the neoplastic plasma cells. This may also explain why thrombosis in the context of IMID-based therapy may be prevented by the use of prophylactic aspirin. In this text, we review the pathogenesis of thrombosis in myeloma, its relation to different chemotherapeutic regimens and the use of thrombo-prophylaxis.

KW - Multiple myeloma

KW - Thrombosis

UR - http://www.scopus.com/inward/record.url?scp=84859791294&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84859791294&partnerID=8YFLogxK

U2 - 10.1179/102453312X13336169156933

DO - 10.1179/102453312X13336169156933

M3 - Article

C2 - 22507814

AN - SCOPUS:84859791294

VL - 17

JO - Hematology

JF - Hematology

SN - 1024-5340

IS - SUPPL. 1

ER -